Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
Recs
Rather than an endorsement of Idera's pipeline, this green thumb represents confidence in their low burn and the volatility of the stock. Having stabilized off a recent spike and plunge (for no discernible reason), Idera is primed to reascend and has all the time in the world to get there.
Recs
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!
Recs
Recs
exiting patents needed for farmuecitical market will reflect son expanded orders and deman for larger supply.
Recs
It´s at it's most
Recs
Not a long-termie, because I'm not personally well into the stock and cannot tell whether they have something unique in their safes to take it out by Easter or not.
But I can tell a stock with such stats and such current price is to go down.
Recs
pharmaceuticals are always fluctuating up and down according to the seasons. summer is a down season.
Recs
Wall Street Pro Pick.
Recs
Hey - it's just a random pick from the top performers list. What do I know? (not much)
Recs
IDERA has cutting edge new science in the field of immunology. They have had their share of followers and detractors over the years, and survived through it all. They have a strong company plan now, good partners, and exciting therapies that will be used to combat aids, cancer, and other human maladies. Above all IDERA has always been an honest, intelligent company that had strived to make a difference in health and science.
Recs
.. I'd give this one a thumbs up ..


RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 11 of 11